

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ni et al.

Docket No.: PF290P1D2

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

For: Pancreas-Derived Plasminogen Activator
Inhibitor

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references A-BW listed on the attached Form SB/08.

Copies of references A-BW were submitted by Applicants or cited by the Examiner in connection with United States Patent Application No. 09/902,684, filed on July 12, 2001, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application No. 09/902,684 for copies of references A-BW.


The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: July 29, 2003

Respectfully submitted,

By 
Melissa J. Pytel
Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 610-5764

KKH/MJP/ba

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Jian Ni
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	6	Attorney Docket Number	PF290P1D2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A	US-4,923,807	08-05-1990	Webb et al.	
	B	US-5,470,970	11-28-1995	Sager et al.	
	C	US-5,804,376	09-08-1998	Braxton et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	D	WO-96/34957	11-07-1996			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Jian Ni
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	6	Attorney Docket Number	PF290P1D2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	E	Barton, G.J., "Protein sequence alignment and database scanning," in: Protein Structure Prediction, A Practical Approach, Sternberg, M.J.E., ed., IRL Press at Oxford University Press, Oxford, UK, pp. 31-63 (August 1996).	
	F	Carrell, R.W. et al., "The Serpins: Evolution and Adaptation in a Family of Protease Inhibitors," <i>Cold Spring Harbor Symp. Quant. Biol.</i> 52:527-535, Cold Spring Harbor Laboratory (1987).	
	G	Cronshagen, U. et al., "A novel protein expressed exclusively in pancreatic cells is proposed to be a serpin," Abstract No. 247, <i>Eur. J. Cell Bio.</i> 94:83, Nature Publishing Group (1993).	
	H	Cunningham, B.C. and Wells, J.A., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," <i>Science</i> 244:1081-1085, American Association for the Advancement of Science (1989).	
	I	Fazioli, F. and Blasi, F., "Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?," <i>TIPS</i> 15:25-29, Elsevier Science (1994).	
	J	George, D.G. et al., "Current Methods in Sequence Comparison and Analysis," in: Macromolecular Sequencing and Synthesis, Selected Methods and Applications, D.H. Schlesinger, ed., Alan R. Liss, Inc. New York, NY, pp. 127-149 (1988).	
	K	Ginsburg, D. et al., "cDNA Cloning of Human Plasminogen Activator-Inhibitor from Endothelial Cells," <i>J. Clin. Invest.</i> 78:1673-1680, American Society for Clinical Investigation (1986).	
	L	Krishnamurti, C. et al., "Stimulation Of Plasminogen Activator Inhibitor Activity In Human Monocytes Infected With Dengue Virus," <i>Am. J. Trop. Med. Hyg.</i> 40:102-107, American Society of Tropical Medicine and Hygiene (1989).	
	M	Kruithof, E.K.O. et al., "Biological and Clinical Aspects of Plasminogen Activator Inhibitor Type 2," <i>Blood</i> 86:4007-4024, Journal of the American Society of Hematology (December 1995).	
	N	Leiper, K. et al., "Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease," <i>J. Clin. Pathol.</i> 47:214-217, BMJ Publishing Group (1994).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Jian Ni
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	6	Attorney Docket Number	PF290P1D2

O	Ngo, J.T. et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: The Protein Folding Problem and Tertiary Structure Prediction, Mertz, Jr., K. and Le Grand, S., eds., Birkhauser, Boston, Massachusetts, pp. 491-495 (1994).
P	Robson, R. and Garnier, J., eds., "Modern ideas and notations relating to primary structure," in: Introduction to Proteins and Protein Engineering, Elsevier, Amsterdam, Holland pp. 41-43 (1986).
Q	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in: Peptide Hormones, Parsons, J.A., eds., University Park Press, Baltimore, Maryland, pp. 5-7 (1976).
R	Sprecher, C.A. et al., "Molecular Cloning, Expression, and Partial Characterization of Two Novel Members of the Ovalbumin Family of Serine Proteinase Inhibitors," <i>J. Biol. Chem.</i> 270:29854-29861, American Society for Biochemistry and Molecular Biology (December 1995).
S	Sun, J. et al., "Gene Structure, Chromosomal Localization, and Expression of the Murine Homologue of Human Proteinase Inhibitor 6 (PI-6) Suggests Divergence of PI-6 from the Ovalbumin Serpins," <i>J. Biol. Chem.</i> 270:16089-16096, American Society for Biochemistry and Molecular Biology (July 1995).
T	Urano, T. et al., "A substrate-like form of plasminogen-activator-inhibitor type 1," <i>Eur. J. Biochem.</i> 209:985-992, Federation of European Biochemical Societies (1992).
U	Wells, J.A., "Additivity of Mutational Effects in Proteins," <i>Biochem.</i> 29:8509-8516, American Chemical Society (1990).
V	Genbank Report, Accession No. Z30585, submitted by Cronshagen, U. et al. (1994).
W	Genbank Report, Accession No. AAA6003, submitted by Ginsburg, D. et al. (January 1995).
X	Genbank Report, Accession No. X16383, submitted by Sawdey, M.S. (February 1995).
Y	Genbank Report, Accession No. D13909, submitted by Mimuro et al. (November 1995).
Z	NCBI Entrez, GenBank Report, Accession No. T52685, from Hillier, L. et al. (February 1995).
AA	NCBI Entrez, GenBank Report, Accession No. F07041, from Auffray, C. et al. (February 1995).
AB	NCBI Entrez, GenBank Report, Accession No. D58484, from Fujiwara, T. et al. (August 1995).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Jian Ni
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	6	Attorney Docket Number	PF290P1D2

	AC	NCBI Entrez, GenBank Report, Accession No. H81869, from Hillier, L. et al. (November 1995).	
	AD	NCBI Entrez, GenBank Report, Accession No. H82168, from Hillier, L. et al. (November 1995).	
	AE	NCBI Entrez, GenBank Report, Accession No. D27259, from Kohara, Y. et al. (November 1995).	
	AF	NCBI Entrez, GenBank Report, Accession No. N34066, from Hillier, L. et al. (January 1996).	
	AG	NCBI Entrez, GenBank Report, Accession No. N41961, from Hillier, L. et al. (January 1996).	
	AH	NCBI Entrez, GenBank Report, Accession No. N86663, from Liew, C.C. (April 1996).	
	AI	NCBI Entrez, GenBank Report, Accession No. C18938, from Fujiwara, T. et al. (October 1996).	
	AJ	NCBI Entrez, GenBank Report, Accession No. C18122, from Fujiwara, T. et al. (October 1996).	
	AK	NCBI Entrez, GenBank Report, Accession No. AA091273, from Liew, C.C. (October 1996).	
	AL	NCBI Entrez, GenBank Report, Accession No. AA104570, from Marra, M. et al. (October 1996).	
	AM	NCBI Entrez, GenBank Report, Accession No. AA147887, from Hillier, L. et al. (December 1996).	
	AN	NCBI Entrez, GenBank Report, Accession No. AA147909, from Hillier, L. et al. (December 1996).	
	AO	NCBI Entrez, GenBank Report, Accession No. AA147917, from Hillier, L. et al. (December 1996).	
	AP	NCBI Entrez, GenBank Report, Accession No. AA168365, from Marra, M. et al. (February 1997).	
	AQ	NCBI Entrez, GenBank Report, Accession No. AA117151, from Marra, M. et al. (February 1997).	
	AR	NCBI Entrez, GenBank Report, Accession No. AA276326, from Marra, M. et al. (April 1997).	
	AS	NCBI Entrez, GenBank Report, Accession No. AA303966, from Adams, M.D. et al. (April 1997).	
	AT	NCBI Entrez, GenBank Report, Accession No. AA296389, from Adams, M.D. et al. (April 1997).	
	AU	NCBI Entrez, GenBank Report, Accession No. AA296506, from Adams, M.D. et al. (April 1997).	
	AV	NCBI Entrez, GenBank Report, Accession No. AA317566, from Adams, M.D. et al. (April 1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Completeness if Known		
			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Jian Ni	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	5	of	6	Attorney Docket Number	PF290P1D2

	AW	NCBI Entrez, GenBank Report, Accession No. AA372832, from Adams, M.D. et al. (April 1997).	
	AX	NCBI Entrez, GenBank Report, Accession No. AA409232, from Ko, M.S.H. et al. (May 1997).	
	AY	NCBI Entrez, GenBank Report, Accession No. AA045132, from Hillier, L. et al. (May 1997).	
	AZ	NCBI Entrez, GenBank Report, Accession No. AA473834, from Marra, M. et al. (June 1997).	
	BA	NCBI Entrez, GenBank Report, Accession No. H09005, from Hillier, L. et al. (June 1997).	
	BB	NCBI Entrez, GenBank Report, Accession No. AA544064, from Marra, M. et al. (August 1997).	
	BC	NCBI Entrez, GenBank Report, Accession No. AA146811, from Hillier, L. et al. (August 1997).	
	BD	NCBI Entrez, GenBank Report, Accession No. AA242969, from Hillier, L. et al. (August 1997).	
	BE	NCBI Entrez, GenBank Report, Accession No. AA562720, from Marra, M. et al. (August 1997).	
	BF	NCBI Entrez, GenBank Report, Accession No. AA542814, from NCI-CGAP (August 1997).	
	BG	NCBI Entrez, GenBank Report, Accession No. AA571334, from Marra, M. et al. (August 1997).	
	BH	NCBI Entrez, GenBank Report, Accession No. C31835, from Kohara, Y. et al. (September 1997).	
	BI	NCBI Entrez, GenBank Report, Accession No. AA589090, from Marra, M. et al. (September 1997).	
	BIJ	NCBI Entrez, GenBank Report, Accession No. H52450, from Hillier, L. et al. (September 1995).	
	BK	NCBI Entrez, GenBank Report, Accession No. AA596670, from Marra, M. et al. (September 1997).	
	BL	NCBI Entrez, GenBank Report, Accession No. C67391, from Kohara, Y. et al. (September 1997).	
	BM	NCBI Entrez, GenBank Report, Accession No. C71498, from Kohara, Y. et al. (September 1997).	
	BN	NCBI Entrez, GenBank Report, Accession No. AA645751, from Marra, M. et al. (October 1997).	
	BO	NCBI Entrez, GenBank Report, Accession No. AA666768, from Marra, M. et al. (November 1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Jian Ni
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	6	of	6	Attorney Docket Number	PF290P1D2

	BP	NCBI Entrez, GenBank Report, Accession No. AA684304, from Marra, M. et al. (December 1997).	
	BQ	NCBI Entrez, GenBank Report, Accession No. AA706757, from Hillier, L. et al. (December 1997).	
	BR	NCBI Entrez, GenBank Report, Accession No. AA738996, from Marra, M. et al. (1998).	
	BS	NCBI Entrez, GenBank Report, Accession No. AA487997, from Hillier, L. et al. (1998).	
	BT	NCBI Entrez, GenBank Report, Accession No. AA852339, from Jia, L. et al. (1998).	
	BU	NCBI Entrez, GenBank Report, Accession No. AA867587, from Marra, M. et al. (1998).	
	BV	NCBI Entrez, GenBank Report, Accession No. AA869929, from Marra, M. et al. (1998).	
	BW	NCBI Entrez, GenBank Report, Accession No. AA869413, from Marra, M. et al. (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--